 Parts 1 and 2 of this trial have been completed with the Recommended Part 3 Phase 2 Dose established at 0.8 mgm2. Part 3 of this trial is enrolling at the MRZ RP2D determined in Phase 1 to assess the combination of MRZ and BEV activity and safety. 